MCID: ORL012
MIFTS: 47

Oral Leukoplakia

Categories: Oral diseases, Rare diseases

Aliases & Classifications for Oral Leukoplakia

MalaCards integrated aliases for Oral Leukoplakia:

Name: Oral Leukoplakia 54
Leukoplakia, Oral 74
Leukoplakia Oral 56

Classifications:



External Ids:

UMLS 74 C0023532

Summaries for Oral Leukoplakia

NIH Rare Diseases : 54 Oral leukoplakia describes a white plaque that does not rub off and cannot be characterized as any other condition. Though it may occur in any part of the mouth, it generally affects the tongue, gums, and inner cheek. Physicians will usually biopsy oral leukoplakia lesions as 20-40% of cases are precancerous or cancerous at the time of biopsy and another 8-15% become cancerous over time. The exact cause of oral leukoplakia is not known. Factors that may increase the risk of developing oral leukoplakia include smoking, alcohol use, vitamin deficiencies, malocclusion, and a weakened immune system.Treatment depends on the biopsy results and the size, appearance, and location of the oral leukoplakia. Removal or ablation of the lesion by surgery, laser, or cryotherapy (use of low temperature) may be recommended.

MalaCards based summary : Oral Leukoplakia, also known as leukoplakia, oral, is related to leukoplakia and squamous cell papilloma. An important gene associated with Oral Leukoplakia is GSTM1 (Glutathione S-Transferase Mu 1), and among its related pathways/superpathways are Cell Cycle, Mitotic and Human cytomegalovirus infection. The drugs Rosiglitazone and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include tongue, cervix and skin, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Oral Leukoplakia

Diseases related to Oral Leukoplakia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Related Disease Score Top Affiliating Genes
1 leukoplakia 31.6 GSTM1 MKI67 PCNA
2 squamous cell papilloma 30.5 CDKN2A TP53
3 verrucous carcinoma 29.9 CCND1 CDKN2A TP53
4 squamous cell carcinoma 29.8 CCND1 CDKN2A MKI67 TP53 TP63 XRCC1
5 in situ carcinoma 29.8 CDKN2A TP53
6 esophageal cancer 29.7 CCND1 CDKN2A GSTM1 TP53
7 oral cancer 29.5 CCND1 CDKN2A GSTM1 PCNA TP53
8 papilloma 29.0 CCND1 CDKN2A PCNA TP53 TP63
9 proliferative verrucous leukoplakia 12.0
10 oral hairy leukoplakia 11.8
11 dyskeratosis congenita 11.6
12 revesz syndrome 11.3
13 oral mucosa leukoplakia 11.3
14 dyskeratosis congenita, autosomal recessive 5 11.2
15 dyskeratosis congenita, autosomal recessive 6 11.2
16 dyskeratosis congenita, autosomal dominant 6 11.2
17 oral squamous cell carcinoma 10.7
18 lichen planus 10.5
19 oral submucous fibrosis 10.5
20 oral lichen planus 10.4
21 brain ependymoma 10.3 MKI67 TP53
22 adenosarcoma 10.3 MKI67 TP53
23 sister chromatid exchange, frequency of 10.3 GSTM1 XRCC1
24 soft tissue sarcoma 10.3 MKI67 TP53
25 bladder squamous cell carcinoma 10.2 CDKN2A TP53
26 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
27 embryonal sarcoma 10.2 MKI67 TP53
28 bladder carcinoma in situ 10.2 CDKN2A TP53
29 vulva squamous cell carcinoma 10.2 CDKN2A TP53
30 scrotal carcinoma 10.2 CDKN2A TP53
31 thyroid lymphoma 10.2 CDKN2A TP53
32 vulvar disease 10.2 CDKN2A TP53
33 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
34 bartholin's gland disease 10.2 CDKN2A TP53
35 anal squamous cell carcinoma 10.2 CDKN2A TP53
36 megaesophagus 10.2 CDKN2A TP53
37 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A TP53
38 isolated cleft lip 10.2 GSTM1 TP63
39 gastric adenosquamous carcinoma 10.2 CDKN2A TP53
40 anogenital venereal wart 10.2 CDKN2A TP53
41 cervix uteri carcinoma in situ 10.2 CDKN2A TP53
42 uterus carcinoma in situ 10.2 CDKN2A TP53
43 meningeal melanomatosis 10.2 CDKN2A TP53
44 benign breast phyllodes tumor 10.2 MKI67 TP63
45 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.2 TP53 TP63
46 endometrial mucinous adenocarcinoma 10.2 CDKN2A MKI67
47 dedifferentiated liposarcoma 10.2 CDKN2A TP53
48 endocervical adenocarcinoma 10.2 CDKN2A TP53
49 penile disease 10.2 CDKN2A TP53
50 ulcerative stomatitis 10.2 TP53 TP63

Graphical network of the top 20 diseases related to Oral Leukoplakia:



Diseases related to Oral Leukoplakia

Symptoms & Phenotypes for Oral Leukoplakia

GenomeRNAi Phenotypes related to Oral Leukoplakia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.33 CCND1 MKI67 PCNA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 CDKN2A PCNA TP53 XRCC1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 CCND1 CDKN2A PCNA TP53 TP63 XRCC1
4 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.26 PCNA TP53 TP63 XRCC1

MGI Mouse Phenotypes related to Oral Leukoplakia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.87 CCND1 CDKN2A PCNA TINF2 TP53 TP63
2 endocrine/exocrine gland MP:0005379 9.85 CCND1 CDKN2A PCNA TINF2 TP53 TP63
3 neoplasm MP:0002006 9.65 CCND1 CDKN2A TP53 TP63 XRCC1
4 no phenotypic analysis MP:0003012 9.63 CDKN2A MKI67 PCNA TINF2 TP53 TP63
5 normal MP:0002873 9.43 CCND1 MKI67 TINF2 TP53 TP63 XRCC1
6 reproductive system MP:0005389 9.1 CCND1 CDKN2A PCNA TINF2 TP53 TP63

Drugs & Therapeutics for Oral Leukoplakia

Drugs for Oral Leukoplakia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
2
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
3
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
4
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137
5
Trioxsalen Approved Phase 2 3902-71-4 5585
6
nivolumab Approved Phase 2 946414-94-4
7
Metformin Approved Phase 2 657-24-9 14219 4091
8
Pembrolizumab Approved Phase 2 1374853-91-4
9
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
10
Fenretinide Investigational Phase 2 65646-68-6
11 Hypoglycemic Agents Phase 2
12 Analgesics, Non-Narcotic Phase 2,Phase 1,Not Applicable
13 Peripheral Nervous System Agents Phase 2,Phase 1,Not Applicable
14 Analgesics Phase 2,Phase 1,Not Applicable
15 Antirheumatic Agents Phase 2,Phase 1,Not Applicable
16 Cyclooxygenase Inhibitors Phase 2,Phase 1,Not Applicable
17 Anti-Inflammatory Agents Phase 2,Phase 1,Not Applicable
18 Cyclooxygenase 2 Inhibitors Phase 2
19 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1,Not Applicable
20 Retinamide Phase 2
21 Pharmaceutical Solutions Phase 1, Phase 2
22 Dermatologic Agents Phase 1, Phase 2,Phase 2
23 Photosensitizing Agents Phase 1, Phase 2,Phase 2
24 Hematoporphyrin Derivative Phase 2
25 Ether Phase 2
26 Dihematoporphyrin Ether Phase 2
27 Hematoporphyrins Phase 2
28 Antineoplastic Agents, Immunological Phase 2
29 Tea Phase 2
30
Aspirin Approved, Vet_approved Phase 1 50-78-2 2244
31
Isotretinoin Approved Phase 1 4759-48-2 5282379 5538
32
Erythromycin Approved, Investigational, Vet_approved Phase 1 114-07-8 441411 12560
33 Antipyretics Phase 1
34 Fibrinolytic Agents Phase 1
35 Platelet Aggregation Inhibitors Phase 1
36 Erythromycin stearate Phase 1
37 Erythromycin Estolate Phase 1
38 Erythromycin Ethylsuccinate Phase 1
39
Heparin Approved, Investigational 9005-49-6 46507594 772
40
Acyclovir Approved Not Applicable 59277-89-3 2022
41
Dapsone Approved, Investigational Not Applicable 80-08-0 2955
42
leucovorin Approved Not Applicable 58-05-9 143 6006
43
Sulindac Approved, Investigational Not Applicable 38194-50-2 1548887 5352
44
Ethanol Approved 64-17-5 702
45
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
46 Antioxidants
47 Protective Agents
48 Hemostatics ,Not Applicable
49 Coagulants
50 Tolonium Chloride

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
2 Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia Completed NCT00369174 Phase 2 rosiglitazone maleate
3 Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00099021 Phase 2 pioglitazone hydrochloride
4 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
5 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
6 Fenretinide in Treating Patients With Leukoplakia of the Mouth Completed NCT00004161 Phase 2 fenretinide;Placebo
7 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Completed NCT00052611 Phase 2 Celecoxib
8 Treatment of Oral Premalignant Lesions With 5-ALA PDT Completed NCT00571974 Phase 1, Phase 2 5-Aminolevulinic Acid (Levulan KerastickTM)
9 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract Completed NCT00453336 Phase 2 Porfimer Sodium
10 Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia Recruiting NCT03692325 Phase 2 Nivolumab
11 Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Active, not recruiting NCT02581137 Phase 2 Metformin Hydrochloride
12 Pembrolizumab in Treating Participants With Leukoplakia Not yet recruiting NCT03603223 Phase 2
13 A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Terminated NCT00176566 Phase 2 Lozenge Intake
14 Pioglitazone for Oral Premalignant Lesions Terminated NCT00951379 Phase 2 Pioglitazone hydrochloride
15 Aspirin Mouthwash in Treating Patients With Oral Leukoplakia Completed NCT01238185 Phase 1 acetylsalicylic acid
16 This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions Not yet recruiting NCT03939364 Phase 1 SBS-101;Placebo
17 Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Terminated NCT00571558 Phase 1 aminolevulinic acid hydrochloride;photodynamic therapy
18 Least Invasive Nonlinear Light Microscopy Unknown status NCT00767442
19 Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity Unknown status NCT01636544 Not Applicable
20 Comparison Between Two Different High Power Ablative Lasers in the Treatment of Oral Leukoplakia Completed NCT03233165 Not Applicable
21 Biomarkers for Oral Cancer Completed NCT00341497
22 8-Hydroxy-2-Deoxyguanosine ,Total Antioxidant Capacity in Oral Premalignant and Malignant Lesions Completed NCT03830710
23 Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy Completed NCT03031899
24 Clinical Research Core Dental Screening Protocol Completed NCT00090818
25 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia Completed NCT00835341
26 Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV) Completed NCT00002026 Not Applicable Acyclovir
27 Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) Completed NCT00002043 Not Applicable Dapsone
28 Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer Recruiting NCT00542373 Not Applicable
29 Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Recruiting NCT03239834
30 A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery Active, not recruiting NCT01355926 Not Applicable
31 A Randomized Study of Sulindac in Oral Premalignant Lesions Active, not recruiting NCT00299195 Not Applicable sulindac;Placebo
32 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Not yet recruiting NCT03682562

Search NIH Clinical Center for Oral Leukoplakia

Genetic Tests for Oral Leukoplakia

Anatomical Context for Oral Leukoplakia

MalaCards organs/tissues related to Oral Leukoplakia:

42
Tongue, Cervix, Skin, Thyroid, Tonsil, Testes, Liver

Publications for Oral Leukoplakia

Articles related to Oral Leukoplakia:

(show top 50) (show all 582)
# Title Authors Year
1
Oral leukoplakia: A diagnostic challenge for clinicians and pathologists. ( 30203899 )
2019
2
Photodynamic therapy in the treatment of oral leukoplakia: A systematic review. ( 30391342 )
2019
3
Malignant transformation of oral leukoplakia treated with carbon dioxide laser: a meta-analysis. ( 30443884 )
2019
4
Podoplanin expression in oral leukoplakia─a prospective study. ( 30638740 )
2019
5
Nail dystrophy and oral leukoplakia in a 3-year-old girl. ( 30675941 )
2019
6
Evaluation of salivary metabolomics in oral leukoplakia and oral squamous cell carcinoma. ( 30714209 )
2019
7
Combined Testing of p16 Tumour-suppressor Protein and Human Papillomavirus in Patients With Oral Leukoplakia and Oral Squamous Cell Carcinoma. ( 30842161 )
2019
8
Evaluation of enzymatic and non-enzymatic antioxidant status and biomarkers of oxidative stress in saliva of patients with oral squamous cell carcinoma and oral leukoplakia: a pilot study. ( 30857448 )
2019
9
Molecular alterations of mitochondrial D-loop in oral leukoplakia. ( 30945332 )
2019
10
"Expression of p16 in oral leukoplakia and oral squamous cell carcinoma and correlation of its expression with individual atypical features". ( 30963022 )
2019
11
Development and validation of nomogram for prediction of malignant transformation in oral leukoplakia: A large-scale cohort study. ( 30980769 )
2019
12
Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. ( 31027907 )
2019
13
Comparison of Er:YAG and Er,Cr:YSGG Laser in the Treatment of Oral Leukoplakia Lesions Refractory to the Local Retinoid Therapy. ( 31081716 )
2019
14
Immunohistochemical study of α-smooth muscle actin expression in oral leukoplakia and oral squamous cell carcinoma. ( 31110418 )
2019
15
An immunohistochemical evaluation of podoplanin expression in oral leukoplakia and oral squamous cell carcinoma to explore its potential to be used as a predictor for malignant transformation. ( 31110440 )
2019
16
Expression of DNA doublestrand repair proteins in oral leukoplakia and the risk of malignant transformation. ( 29928356 )
2018
17
Immunoexpression of SOX-2 in oral leukoplakia. ( 29938872 )
2018
18
Liquid-based oral brush cytology in the diagnosis of oral leukoplakia using a modified Bethesda Cytology system. ( 29957892 )
2018
19
Mature dendritic cell density is affected by smoking habit, lesion size, and epithelial dysplasia in oral leukoplakia samples. ( 30056280 )
2018
20
Low level laser therapy reduces oral leukoplakia lesion size: Results from a preliminary study. ( 30098877 )
2018
21
Effect of TP53 rs1042522 on the susceptibility of patients to oral squamous cell carcinoma and oral leukoplakia: a meta-analysis. ( 30126398 )
2018
22
CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. ( 30160018 )
2018
23
Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer. ( 30172723 )
2018
24
A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma. ( 30210912 )
2018
25
Treatment Outcome of Oral Leukoplakia with Er:YAG Laser: A 5-Year Follow-Up Prospective Comparative Study. ( 30339489 )
2018
26
Prevention of Malignant Transformation of Oral Leukoplakia and Oral Lichen Planus Using Laser: An Observational Study ( 30583693 )
2018
27
Expression of P53 Protein and Ki-67 Antigen in Oral Leukoplakia with Different Histopathological Grades of Epithelial Dysplasia. ( 30596042 )
2018
28
Detection of salivary heat shock protein 27 by enzyme-linked immunosorbent assay and its correlation with histopathology of oral leukoplakia. ( 30651672 )
2018
29
Primary Clinical Evaluation of Photodynamic Therapy With Oral Leukoplakia in Chinese Patients. ( 30723421 )
2018
30
T cells are involved in the induction of macrophage phenotypes in oral leukoplakia and squamous cell carcinoma-a preliminary report. ( 29108105 )
2018
31
A clinical diagnosis of oral leukoplakia; A guide for dentists. ( 29274164 )
2018
32
Malignant transformation of Taiwanese patients with oral leukoplakia: A nationwide population-based retrospective cohort study. ( 29428194 )
2018
33
Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma. ( 29436667 )
2018
34
Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment. ( 29443777 )
2018
35
Oral leukoplakia remains a challenging condition. ( 29480606 )
2018
36
Knowledge about oral leukoplakia for use at different levels of expertise, including patients. ( 29480645 )
2018
37
Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia. ( 29588189 )
2018
38
Expression and oncogenic properties of membranous Notch1 in oral leukoplakia and oral squamous cell carcinoma. ( 29620248 )
2018
39
Evaluation of Collagen in Leukoplakia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinomas Using Polarizing Microscopy and Immunohistochemistry ( 29699065 )
2018
40
Determination and diagnostic value of CA9 mRNA in peripheral blood of patients with oral leukoplakia. ( 29745265 )
2018
41
CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma. ( 29805639 )
2018
42
Immunohistochemical Expression of Podoplanin in Clinical Variants of Oral Leukoplakia and Its Correlation With Epithelial Dysplasia. ( 27153448 )
2018
43
Malignant transformation of oral leukoplakia in a patient with dyskeratosis congenita. ( 28923296 )
2017
44
Vascular alterations after photodynamic therapy mediated by 5-aminolevulinic acid in oral leukoplakia. ( 28004205 )
2017
45
Semiquantifiable angiogenesis parameters in association with the malignant transformation of oral leukoplakia. ( 28036153 )
2017
46
ALDH1 and podoplanin expression patterns predict the risk of malignant transformation in oral leukoplakia. ( 28123562 )
2017
47
Predictive value of the combination of SMAD4 expression and lymphocyte infiltration in malignant transformation of oral leukoplakia. ( 28256094 )
2017
48
Hospital-based epidemiological and clinical characterisation of the malignant transformation of oral leukoplakia in a Chinese population. ( 28276054 )
2017
49
Predictive value of p63, ki-67, and survivin expression in oral leukoplakia: A tissue microarray study. ( 28346726 )
2017
50
Evaluation of Different Laser-Supported Surgical Protocols for the Treatment of Oral Leukoplakia: A Long-Term Follow-Up. ( 28426376 )
2017

Variations for Oral Leukoplakia

Expression for Oral Leukoplakia

Search GEO for disease gene expression data for Oral Leukoplakia.

Pathways for Oral Leukoplakia

Pathways related to Oral Leukoplakia according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 CCND1 CDKN2A PCNA TINF2 TP53
2
Show member pathways
12.75 CCND1 CDKN2A PCNA TP53
3
Show member pathways
12.74 CDKN2A PCNA TP53 TP63
4
Show member pathways
12.64 CCND1 CDKN2A PCNA TP53
5 12.62 CCND1 CDKN2A GSTM1 TP53
6
Show member pathways
12.54 CCND1 CDKN2A GSTM1 TP53
7
Show member pathways
12.47 CCND1 PCNA TP53 XRCC1
8
Show member pathways
12.31 CCND1 CDKN2A PCNA TP53
9 12.25 CCND1 CDKN2A TP53 TP63
10
Show member pathways
12.21 CCND1 PCNA TP53
11
Show member pathways
12.19 CCND1 CDKN2A TP53
12
Show member pathways
12.15 CCND1 CDKN2A TP53
13 12.09 CCND1 CDKN2A TP53
14 12.05 CCND1 CDKN2A PCNA TP53
15 12.03 CCND1 CDKN2A PCNA TP53
16 11.96 CCND1 CDKN2A TP53
17 11.86 PCNA TP53 TP63
18 11.78 CCND1 CDKN2A TP53
19 11.76 CCND1 CDKN2A TP53
20 11.73 CDKN2A PCNA TP53
21 11.64 CCND1 CDKN2A MKI67 PCNA TP53 TP63
22 11.63 CCND1 PCNA TP53
23 11.5 CCND1 CDKN2A TP53
24 11.47 CDKN2A GSTM1 TP53
25 11.22 CCND1 XRCC1
26 11.21 CCND1 CDKN2A TP53
27 11.14 CDKN2A TP53
28 11.08 PCNA TP53
29 11.08 CCND1 PCNA TP53
30 10.95 CDKN2A TP53
31 10.84 CCND1 PCNA TP53
32
Show member pathways
10.47 CDKN2A TP53 TP63

GO Terms for Oral Leukoplakia

Cellular components related to Oral Leukoplakia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 CCND1 CDKN2A PCNA TINF2 TP53 TP63
2 nuclear chromatin GO:0000790 9.43 TP53 TP63 XRCC1
3 nuclear chromosome, telomeric region GO:0000784 9.13 PCNA TINF2 XRCC1
4 nuclear body GO:0016604 8.92 MKI67 PCNA TINF2 TP53

Biological processes related to Oral Leukoplakia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.76 CCND1 CDKN2A MKI67 TP53
2 cellular response to DNA damage stimulus GO:0006974 9.62 CCND1 PCNA TP53 XRCC1
3 base-excision repair GO:0006284 9.54 TP53 XRCC1
4 regulation of mitotic nuclear division GO:0007088 9.52 CCND1 MKI67
5 liver regeneration GO:0097421 9.51 CCND1 PCNA
6 protein tetramerization GO:0051262 9.49 TP53 TP63
7 cell aging GO:0007569 9.48 TP53 TP63
8 cell proliferation GO:0008283 9.46 MKI67 PCNA TP53 TP63
9 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.43 TP53 TP63
10 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.4 TP53 TP63
11 nucleotide-excision repair, DNA gap filling GO:0006297 9.37 PCNA XRCC1
12 replicative senescence GO:0090399 9.26 CDKN2A TP53
13 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
14 negative regulation of protein ADP-ribosylation GO:0010836 8.62 TINF2 XRCC1

Molecular functions related to Oral Leukoplakia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.63 CDKN2A MKI67 PCNA TINF2 TP53 TP63
2 disordered domain specific binding GO:0097718 9.32 CDKN2A TP53
3 histone acetyltransferase binding GO:0035035 9.26 PCNA TP53
4 damaged DNA binding GO:0003684 9.13 PCNA TP63 XRCC1
5 enzyme binding GO:0019899 9.02 CCND1 GSTM1 PCNA TP53 XRCC1

Sources for Oral Leukoplakia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....